Cargando…

Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients

OBJECTIVE: This study attempted to identify altered metabolism and pathways related to non-Hodgkin’s lymphoma (NHL) and myeloma patients. MATERIALS AND METHODS: In this retrospective study, we collected plasma samples from 11 patients-6 healthy controls with no evidence of any blood cancers and 5 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Medriano, Carl Angelo D., Na, Jinhyuk, Lim, Kyung-min, Chung, Jin-ho, Park, Youngja H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royan Institute 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448325/
https://www.ncbi.nlm.nih.gov/pubmed/28580307
http://dx.doi.org/10.22074/cellj.2017.4412
_version_ 1783239532616876032
author Medriano, Carl Angelo D.
Na, Jinhyuk
Lim, Kyung-min
Chung, Jin-ho
Park, Youngja H.
author_facet Medriano, Carl Angelo D.
Na, Jinhyuk
Lim, Kyung-min
Chung, Jin-ho
Park, Youngja H.
author_sort Medriano, Carl Angelo D.
collection PubMed
description OBJECTIVE: This study attempted to identify altered metabolism and pathways related to non-Hodgkin’s lymphoma (NHL) and myeloma patients. MATERIALS AND METHODS: In this retrospective study, we collected plasma samples from 11 patients-6 healthy controls with no evidence of any blood cancers and 5 patients with either multiple myeloma (n=3) or NHL (n=2) during the preliminary study period. Samples were analyzed using quadrupole time-of-flight liquid chromatography mass spectrometry (LC-MS). Significant features generated after statistical analyses were used for metabolomics and pathway analysis. RESULTS: Data after false discovery rate (FDR) adjustment at q=0.05 of features showed 136 for positive and 350 significant features for negative ionization mode in NHL patients as well as 262 for positive and 98 features for negative ionization mode in myeloma patients. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis determined that pathways such as steroid hormone biosynthesis, ABC transporters, and arginine and proline metabolism were affected in NHL patients. In myeloma patients, pyrimidine metabolism, carbon metabolism, and bile secretion pathways were potentially affected by the disease. CONCLUSION: The results have shown tremendous differences in the metabolites of healthy individuals compared to myeloma and lymphoma patients. Validation through quantitative metabolomics is encouraged, especially for the metabolites with significantly expression in blood cancer patients.
format Online
Article
Text
id pubmed-5448325
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Royan Institute
record_format MEDLINE/PubMed
spelling pubmed-54483252017-06-02 Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients Medriano, Carl Angelo D. Na, Jinhyuk Lim, Kyung-min Chung, Jin-ho Park, Youngja H. Cell J Original Article OBJECTIVE: This study attempted to identify altered metabolism and pathways related to non-Hodgkin’s lymphoma (NHL) and myeloma patients. MATERIALS AND METHODS: In this retrospective study, we collected plasma samples from 11 patients-6 healthy controls with no evidence of any blood cancers and 5 patients with either multiple myeloma (n=3) or NHL (n=2) during the preliminary study period. Samples were analyzed using quadrupole time-of-flight liquid chromatography mass spectrometry (LC-MS). Significant features generated after statistical analyses were used for metabolomics and pathway analysis. RESULTS: Data after false discovery rate (FDR) adjustment at q=0.05 of features showed 136 for positive and 350 significant features for negative ionization mode in NHL patients as well as 262 for positive and 98 features for negative ionization mode in myeloma patients. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis determined that pathways such as steroid hormone biosynthesis, ABC transporters, and arginine and proline metabolism were affected in NHL patients. In myeloma patients, pyrimidine metabolism, carbon metabolism, and bile secretion pathways were potentially affected by the disease. CONCLUSION: The results have shown tremendous differences in the metabolites of healthy individuals compared to myeloma and lymphoma patients. Validation through quantitative metabolomics is encouraged, especially for the metabolites with significantly expression in blood cancer patients. Royan Institute 2017 2017-05-17 /pmc/articles/PMC5448325/ /pubmed/28580307 http://dx.doi.org/10.22074/cellj.2017.4412 Text en Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Medriano, Carl Angelo D.
Na, Jinhyuk
Lim, Kyung-min
Chung, Jin-ho
Park, Youngja H.
Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title_full Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title_fullStr Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title_full_unstemmed Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title_short Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin’s Lymphoma Patients
title_sort liquid chromatography mass spectrometry-based metabolite pathway analyses of myeloma and non-hodgkin’s lymphoma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448325/
https://www.ncbi.nlm.nih.gov/pubmed/28580307
http://dx.doi.org/10.22074/cellj.2017.4412
work_keys_str_mv AT medrianocarlangelod liquidchromatographymassspectrometrybasedmetabolitepathwayanalysesofmyelomaandnonhodgkinslymphomapatients
AT najinhyuk liquidchromatographymassspectrometrybasedmetabolitepathwayanalysesofmyelomaandnonhodgkinslymphomapatients
AT limkyungmin liquidchromatographymassspectrometrybasedmetabolitepathwayanalysesofmyelomaandnonhodgkinslymphomapatients
AT chungjinho liquidchromatographymassspectrometrybasedmetabolitepathwayanalysesofmyelomaandnonhodgkinslymphomapatients
AT parkyoungjah liquidchromatographymassspectrometrybasedmetabolitepathwayanalysesofmyelomaandnonhodgkinslymphomapatients